GlucoModicum’s first-of-its-kind, proprietary wearable device, the Talisman, utilizes magnetohydrodynamic (MHD) technology. MHD applies a small amount of energy directly to interstitial fluid for fast extraction of a glucose sample. Phillips-Medisize incorporated specialized human-centered design principles that are helping to streamline product development, ensure usability and position GlucoModicum for production and commercialization once in-depth clinical studies are completed and regulatory approval is obtained from appropriate notified bodies.
COLLABORATING TO ENHANCE PATIENT COMFORT AND CONVENIENCE
Challenges
Supporting future commercialization efforts for this first-of-its-kind, proprietary continuous glucose monitor (CGM) solution demanded fully integrated MedTech product planning, design, development and manufacturing expertise
Ensuring patient safety, comfort and compliance meant designing for heightened usability—which required stringent quality assurance measures and rigorous testing
Addressing strict regulatory requirements called for specialized experience and a proven track record bringing medical-grade wearables to market
Solution
Phillips-Medisize employed a human-centered design approach that was crucial in streamlining product development—examining product usefulness, usability, desirability and manufacturability
Seamless collaboration between GlucoModicum and Phillips-Medisize accelerated innovation, expediting development of 10 product iterations over 2 years
Collaborative synergy will help enable hundreds of millions of devices and sensors to be produced once GlucoModicum receives regulatory approval from appropriate notified bodies and is ready for mass production
Benefits
Phillips-Medisize’s rapid yet collaborative product iteration saved GlucoModicum several years’ worth of product planning and development
Shared commitment drove successful completion of usability studies and ongoing product refinement
Experience in front-end innovation, human-centered design and usability testing proved crucial to the product development process
Overview
To bring this proprietary, non-invasive technological innovation to life, GlucoModicum sought a world-class contract development and manufacturing organization (CDMO) with deep experience in electronics, human-centered design, connectivity, software, complex regulatory compliance, miniaturization and more. Phillips-Medisize, a Molex company, leveraged over 60 years of globally integrated MedTech expertise to help GlucoModicum incorporate proprietary MHD technology with advanced biosensors and specialized algorithms. Together, the team of Phillips-Medisize and GlucoModicum accelerated the design and development of a precise, affordable and convenient CGM solution.
Disclaimer:
The product in this case study has not obtained a CE marking applicable to the health, safety and environmental regulations of the European Union, and has not been reviewed or cleared for use by the U.S. Food and Drug Administration or comparable health regulatory authorities in other jurisdictions.
Featured Resources
